

SUBJECT: PROGRAMME AND POLICY COMMITTEE CHAIR REPORT

Category: For Information

Section A: Introduction

- This report provides the Board with an overview of the activities of the Programme and Policy Committee (PPC) since the Committee Chair last reported to the Board in December 2020.
- The PPC convened by videoconference on 2 February 2021 for an informal discussion on two topics: (i) the COVAX Buffer for high-risk groups in humanitarian situations, and (ii) on changes to the Partners' Engagement Framework (PEF) approach for Gavi 5.0. The PPC comments from the informal meeting helped shape the work on the COVAX Buffer that came back to the PPC for decision at a virtual meeting on 1 March 2021.
- The PPC met virtually on 19-20 May 2021. During the meeting, the Committee discussed a number of important topics for the Alliance and agreed on recommendations which are being put forward to the Board at its June meeting for consideration.
- The PPC Chair report is attached in the form of a presentation as Annex A and the PPC recommendations to the Board are attached as Annex B.

Annexes

Annex A: PPC Chair report

Annex B: PPC recommendations to Gavi Alliance Board

PROGRAMME AND POLICY COMMITTEE CHAIR REPORT

BOARD MEETING

Helen Rees

23-24 June 2021, Virtual Meeting



PPC Meeting, 1 March 2021

- PPC made a recommendation to the Gavi Alliance Board on key elements of the COVAX Buffer, including the:
 - Establishment and scope of the Humanitarian Buffer;
 - Approval US\$ 150 million for delivery costs up to 5% be used to support the deployment of the Humanitarian Buffer; and
 - Delegation of decision making on Humanitarian Buffer dose allocation to the Inter Agency Standing Committee (IASC) Emergency Directors Group.
- This recommendation was subsequently approved by the Gavi Alliance Board at its meeting on 22 March 2021.

PPC Meeting, 19-20 May 2021

Discussion and Guidance Items:

- CEO Update
- Strategic Partnership with India

Recommendations to the Board:

- COVAX update (*Agenda Item 06*)
- Fiduciary Risk Assurance and Financial Management of Gavi Grants in Gavi 5.0 (*Agenda Item 07*)
- Civil Society and Community Engagement Approach (*Agenda Item 08*)

PPC Meeting, 19-20 May 2021

Recommendations to the Board (*continued*):

- Yellow Fever Diagnostics Capacity Strengthening (*consent agenda – Doc 01f*)
- Gavi 5.0: Measurement Framework (*consent agenda – Doc 01f*)
- Gavi 5.0: Market Shaping (*consent agenda – Doc 01f*)
- Gavi 5.0: Innovation Strategy (*consent agenda – Doc 01f*)

PPC Meeting, 19-20 May 2021

CEO Update:

- PPC members queried the ongoing impact of COVID-19 on routine immunisation (RI)
 - Expressed concern over the ripple effect of the suspension of the Serum Institute of India (SII) exports and noted the importance of scaling up production and supplies
 - Highlighted polio investments as critical in maintaining results achieved so far in the context of COVID-19 disruptions
 - Requested that the Secretariat provide more detail on additional Gavi staffing needs, notably the Senior Country Managers (SCMs) positions, and the resources needed for delivery and partners across the Alliance
-

PPC Meeting, 19-20 May 2021

Strategy, Programmes and Partnerships:

- PPC members noted on the yellow fever diagnostic capacity strengthening that there has been clear progress towards the established indicators with a relatively small investment of Gavi resources, and agreed to put this recommendation on the consent agenda for the June 2021 Board meeting.
- On the proposed changes to the structure of the PEF support to partners at the global and regional levels, the PPC requested that several outstanding questions be clarified prior to the Board's consideration of the recommendation put forward by the PPC.

PPC Meeting, 19-20 May 2021

COVAX AMC Support to India:

- PPC members acknowledged the accomplishments achieved in India with Gavi support, notably the improvements to immunisation coverage, and generally agreed that there is a need for continued investment in India
- Highlighted that Gavi's partnership with India must be catalytic and must support the government in building the capacity of its domestic institutions
- Underscored the need for flexibility in the scope of the partnership, considering the substantial proportion of children who drop out need to be addressed to prevent future risk of outbreaks
- On the question of transition, it was suggested that a subnational strategy, including a comprehensive mapping of community institutions including local CSOs, will be an important aspect to ensure sustainability

PPC Meeting, 19-20 May 2021

Additional items placed on consent agenda:

- **Gavi 5.0: Market Shaping Strategy**
 - PPC members recognised the extensive consultations with stakeholders and the alignment across the Alliance in the development of the strategy.
 - Welcomed the tailored approach with shared risks and expanding the strategy to foster a sustainably competitive future supplier base support
- **Gavi 5.0: Measurement Framework**
 - PPC members commended the alignment with the IA2030 agenda
 - Endorsed the proposal to refer to 2019 as a baseline for the indicators
 - Emphasised the importance of establishing targets in order for donors to set their Key Performance Indicators (KPIs) and targets

PPC Meeting, 19-20 May 2021

Additional items placed on consent agenda (*continued*):

- Gavi 5.0: Innovation Strategy
 - PPC members provided guidance on proposed priorities to underpin a unifying innovation approach set out in the paper, including on the creation of new advisory bodies
 - Supported the recommendation for an initial investment on the Vaccine Innovation Prioritisation Strategy (VIPS) for 2021-2023 to incentivise development of the three VIPS innovation priorities: (i) clarifying the potential demand and willingness-to-pay, (ii) defining investment cases and understanding the need for and design of push and pull funding mechanisms, and (iii) generating evidence of programmatic impact
-

PPC Meeting, 19-20 May 2021

PPC Recommendations to the Board:

- Listed in Annex B
- Further details from the PPC discussions contained in the relevant papers to the Board, as listed in Slides 3-4

Thank you



REVIEW OF DECISIONS

PROGRAMME AND POLICY COMMITTEE
19-20 May 2021, Virtual Meeting

Decision 1: Strategy, Programmes and Partnerships: Progress, Risk & Challenges (1/2)

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** an extension through the end of 2022 of the currently forecasted amount which remains within the initially approved envelope of US\$ 8.2 million authorised for the 2019-2021 period for costs related to the procurement and distribution of laboratory reagents, supplies, and equipment for yellow fever diagnostic capacity strengthening through a diagnostic procurement mechanism based on Gavi's existing application, review, and approval processes as set forth in Annex E to Doc 03; and

Decision 1: Strategy, Programmes and Partnerships: Progress, Risk & Challenges (2/2)

- b) **Approve** the new Partners' Engagement Framework (PEF) structure for support to partners at the global and regional levels across three new categories replacing Foundational Support and Special Investments in Strategic Focus Areas: (a) WHO and UNICEF: global and regional functions; (b) other partners: Tailored agreements for co-ordination/prioritisation of immunisation agendas; and (c) Global/Regional partners: Time limited, catalytic investments in activities in zero-dose and other strategic priorities.

Decision 2: Gavi 5.0: Measurement Framework

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it **approve** the proposed targets for selected Gavi 5.0 mission and strategy performance indicators in Annex D to Doc 04, noting that:

- a) The targets will be measured against a 2019 baseline;
- b) The targets are aligned with Immunization Agenda (IA) 2030;
- c) The targets are established under the assumption that COVID-19-related disruptions to immunisation programmes will be limited in 2021 and beyond; however if they are greater or extend longer than assumed the Secretariat may request the Board to adjust the targets; and
- d) Targets for remaining mission and strategy performance indicators in Annex C to Doc 04 will be brought for approval later this year.

Decision 3: Fiduciary Risk Assurance and Financial Management of Gavi Grants in Gavi 5.0

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

- a) **Approve** the approach set forth in Annex D to Doc 05 to strengthen fiduciary risk assurance and financial management of Gavi grants in Gavi 5.0; and
- b) **Approve** the associated investment of US\$ 139 million for 2022-2025, in addition to the US\$ 25 million of bridge funding previously approved by the Board for 2021, for an overall amount of US\$ 164 million for the approach in Gavi 5.0 to be used for the duration of the strategic period (2021-2025).

Decision 4: Gavi 5.0: Market Shaping Strategy

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

Approve the Market Shaping Strategy 5.0 as set out in Annex D to Doc 06.

Decision 5: Civil Society and Community Engagement Approach

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

Approve the Gavi Civil Society and Community Engagement Approach as set out in Annex C to Doc 07, recognising the need to closely monitor, learn and refine and bring back to the PPC and Board for guidance as needed.

Decision 6: COVAX update (1/2)

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board:

- a) That it **consider** Option 2 for the future participation model for Self-Financing Participants (SFPs) and the proposal to unify terms and conditions as set out in Annex E to Doc 08 subject to additional information including risk considerations requested by the Programme and Policy Committee being made available to the Board and subject to the analysis of the three models as recommended by the Audit and Finance Committee;
 - b) That it **approve** the design of the COVID-19 Delivery and System Strengthening (CDSS) envelope and cross-cutting delivery elements as set out in Annex F to Doc 08 and associated funding of US\$ 775 million pending confirmation of availability of funding by the Gavi Alliance Audit and Finance Committee (AFC); and
-

Decision 6: COVAX update (2/2)

- c) Recognising the emergency context, that it **delegate** to the Secretariat, with support from partners WHO and UNICEF, the authority to allot and disburse up to 30% of COVID-19 Delivery and System Strengthening (CDSS) funds to scale-up delivery of COVID-19 vaccines without requiring independent review for rapid disbursement and utilising existing programmatic and fiduciary risk mitigation mechanisms such as those used in emergency and humanitarian contexts on a no regrets basis.

Decision 7: Gavi 5.0: Innovation Strategy

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that it:

Approve an initial investment of up to US\$ 5 million for the Vaccine Innovation Prioritisation Strategy (VIPS) for costs related to short-term (2021-2023) activities to provide guidance for and incentivise development of the three VIPS innovation priorities, namely clarifying the potential demand and willingness-to-pay, defining investment cases and understanding the need for and design of push and pull funding mechanisms, and generating evidence of programmatic impact, pending confirmation of availability of funding by the Gavi Alliance Audit and Finance Committee (AFC) at its meeting on 7 June 2021.

